Skip to content

Evaluation of Immunogenicity of Different Tick Borne Encephalitis (TBE) Fast Protective Traveler Schemes With Inactivated TBE Whole Virus Vaccine

Clinical Study to Test the Immunogenicity of Variant Schedules for TBE Rapid Immunisation Using Inactivated TBE (FSME) Vaccine

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00890422
Acronym
immunisation
Enrollment
99
Registered
2009-04-29
Start date
2007-03-31
Completion date
2010-07-31
Last updated
2009-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tick Borne Encephalitis

Keywords

encephalitis, FSME, central european encephalitis

Brief summary

The study aims to answer this question: whether adequate immunity can be achieved in a short time, that is, by a rapid immunisation process, using at least one of 3 new TBE immunisation schedules? The investigators will test the immunogenicity (the degree of immunity achieved) of each of the immunisation schedules at various times after the injections. If the results of this clinical study are positive, it may then be possible to develop the most successful immunisation schedule so that it can be used routinely. This means that the results of the clinical study have an enormous practical value in preventing TBE in people travelling or moving into areas with a high TBE risk.

Detailed description

The data from at least 99 individuals will be needed if the study is to draw reliable conclusions. One-third of these individuals will receive 3 injections in all: 2 on the first day and the third injection 4 days later (immunisation schedule 1). Another one-third will receive 2 injections in all: one on the first day and one injection 4 days later (immunisation schedule 2). The remaining one-third will also receive 2 injections, both of these on the first day (immunisation schedule 3). Participants will be assigned completely randomly (by chance) to one of these three groups. So each participant stands a 33% chance (a 1:2 chance) of receiving any one particular immunisation schedule. If you agree to take part, the process will be as follows: Brief Overview of the Course of the Clinical Study: Vaccination scheme 1 Vaccination scheme 2 Vaccination scheme 3 Vaccinations: I = Vaccination with FSME-IMMUN 0,5ml * Scheme 1: 2 vaccinations at U1 (day 0), one injection into the left and the right upper arm each, 1 vaccination at U2 (day 4), injection into the left upper arm * Scheme 2: one vaccination at U1 (day 0) and at U2 (day 4), injections into the left upper arm each * Scheme 3: 2 vaccinations at U1 (day 0), one injection into the left and the right upper arm each

Interventions

BIOLOGICALFSME vaccination (FSME-Immun)

intra muscular 0.5 ml

Sponsors

Baxter Healthcare Corporation
CollaboratorINDUSTRY
ASOKLIF
CollaboratorUNKNOWN
Elisabethinen Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* written informed consent * FSME antibody level \< 7IU/ml (ELISA), retrospective * FSME antibody (IgG) \< 63 VIEU/ml (ELISA), retrospective * FSME antibody (IgM) negative * FSME antibody inhibition capacity \<1:10-retrospective * available for the next 56 days

Exclusion criteria

* age not 19 or over 65 * pregnancy * risk of becoming pregnant

Design outcomes

Primary

MeasureTime frame
achievement of FSME-Antibody-level (IgG) >25IU/ml at visit U2, U3, U4, U5, U6, U7, U8 and U9-yes/no achievement of FSME antibody-level (IgG) of >126VIEU/ml at U2, U3;U4, U5, U6, U7, U8 and U9-yes/noU2 (=day4) U3 (=day7) U4 (=day10) U5 (=day 14) U6 (=day21) U7 (=day28) U8 (=day42) U9 (=day56)

Secondary

MeasureTime frame
FSME antibody level at U2, U3, U4, U5, U6, U7, U8 and U9U2 (=day4) U3 (=day7) U4 (=day10) U5 (=day 14) U6 (=day21) U7 (=day28) U8 (=day42) U9 (=day56)

Countries

Austria, Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026